Patents Examined by Adam Weidner
-
Patent number: 11718663Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.Type: GrantFiled: January 10, 2018Date of Patent: August 8, 2023Assignees: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.Inventors: Koji Tamada, Yukimi Sakoda, Tetsuya Nakatsura, Keigo Saito
-
Patent number: 11718674Abstract: An isolated monoclonal antibody, or an antigen-binding portion thereof, that specifically binds human PD0-L1. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immuneconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the antibody or antigen-binding portion thereof.Type: GrantFiled: August 30, 2021Date of Patent: August 8, 2023Assignee: BEIJING MABWORKS BIOTECH CO., LTD.Inventors: Jiangmei Li, Wenqi Hu, Feng Li
-
Patent number: 11713470Abstract: Provided herein are nucleic acids for expressing modified ligand-gated ion channel proteins in excitable cells or secretory cells, such as nerves and neurons and optionally including viral sequences, such as Adeno-associated virus sequences, for delivery to excitable cells or secretory cells of a patient. Also provided herein are methods of modulating cell membrane potentials in an excitable cell or secretory cell, and for treatment of a disease or disorder associated with the nervous system in a patient, such as chronic pain or itch.Type: GrantFiled: March 20, 2018Date of Patent: August 1, 2023Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Rebecca Seal, Cynthia Mary Arokiaraj
-
Patent number: 11708403Abstract: Provided are antibodies and antigen-binding fragments thereof that bind specifically to human complement factor C2 and are capable of inhibiting activation of the classical and lectin pathways of the complement system. The antibodies and antigen-binding fragment exhibit improved manufacturability, pharmacokinetics, and antigen sweeping. Also provided are pharmaceutical compositions comprising the antibodies and antigen-binding fragments, nucleic acids and vectors encoding the antibodies and antigen-binding fragments, host cells comprising the nucleic acids or vectors, and methods of making and using the antibodies and antigen-binding fragments. The antibodies and antigen-binding fragments can be used to inhibit the classical pathway of complement activation in a subject, e.g., a human. The antibodies and antigen-binding fragments can also be used to inhibit the lectin pathway of complement activation in a subject, e.g., a human.Type: GrantFiled: January 10, 2022Date of Patent: July 25, 2023Assignee: ARGENX BVInventors: Christophe Blanchetot, Hans De Haard
-
Patent number: 11702465Abstract: Monoclonal antibodies that specifically bind the F1 antigen of Yersinia pestis with high affinity are described. Use of the monoclonal antibodies for the detection of Y. pestis infection and the diagnosis of plague are also described. Immunoconjugates of the monoclonal antibodies and a radionuclide can also be used for the treatment of a Y. pestis infection.Type: GrantFiled: September 25, 2020Date of Patent: July 18, 2023Assignee: Triad National Security, LLCInventors: Antonietta Maria Lillo, Nileena Velappan, Armand Earl Ko Dichosa, Stosh Anthony Kozimor, Laura Margaret Lilley
-
Patent number: 11701405Abstract: Nucleic acid molecules that include a nucleotide sequence encoding a chimeric antigen receptor (CAR) and a nucleotide sequence encoding a protease sensitive scFv, wherein the chimeric antigen receptor comprises: an scFv targeting a tumor antigen, a spacer, a transmembrane domain, a co-stimulatory domain, and a CD3? signaling domain; and the protease-sensitive scFv and the scFv target the same tumor antigen are described.Type: GrantFiled: January 25, 2019Date of Patent: July 18, 2023Assignee: City of HopeInventors: Xiuli Wang, Stephen J. Forman, Lawrence Stern, Christine E. Brown, Joseph Cohen
-
Patent number: 11702470Abstract: Provided herein are methods for promoting axonal regeneration of sensory neurons and functional recovery of neurons following peripheral nerve injury in a subject experiencing aging-dependent nerve regenerative decline, the method comprising administering to a subject in need thereof an effective amount of an isolated binding molecule which specifically binds to CXCL13.Type: GrantFiled: June 8, 2021Date of Patent: July 18, 2023Assignee: IMPERIAL COLLEGE INNOVATIONS LIMITEDInventors: Simone Di Giovanni, Luming Zhou
-
Patent number: 11698378Abstract: This disclosure relates to methods of determining the amount of post translational modification (PTM) associated with one or more tau peptide fragments of a tau protein in a sample, and methods of evaluating a subject for having a tauopathy, the methods comprising, in part, determining the amount of post translational modification (PTM) associated with one or more tau peptide fragments of a tau protein in a sample, and comparing the amount of the tau PTMs associated with one or more tau peptide fragments with one or more reference levels for the tau peptide fragments, thereby determining whether a subject has a tauopathy.Type: GrantFiled: September 23, 2016Date of Patent: July 11, 2023Assignee: Children's Medical Center CorporationInventors: Judith AJ Steen, Hanno Steen, Waltraud Mair, Jan Muntel, Shaojun Tang
-
Patent number: 11684676Abstract: Antibody-drug conjugates, compositions thereof, and methods use. The antibody-drug conjugates include a fusion protein comprising an antibody covalently linked to an ADP-ribosyl cyclase protein via a peptide linker moiety at one or more of a C-terminus or N-terminus of a heavy or light chain of the antibody, a NAD or NMN analogue, and a payload such that the NAD or NMN analogue is conjugated to both the payload and the ADP-ribosyl cyclase protein.Type: GrantFiled: May 10, 2021Date of Patent: June 27, 2023Assignee: University of Southern CaliforniaInventors: Yong Zhang, Zhefu Dai, Xiao-Nan Zhang
-
Patent number: 11685903Abstract: A method of generating protein-induced pluripotent stem cells by delivering bacterially expressed reprogramming proteins into nuclei of starting somatic cells using the QQ-protein transduction technique, repeating several cell reprogramming cycles for creating reprogrammed protein-induced pluripotent stem cells, moving the reprogrammed cells into a feeder-free medium for expansion, and expanding and passaging the reprogrammed cells in a whole dish for generating homogeneous piPS cells. Also provided are the piPCS cells formed using this method and uses thereof.Type: GrantFiled: April 15, 2020Date of Patent: June 27, 2023Assignee: Wayne State UniversityInventors: Jianjun Wang, Qianqian Li
-
Patent number: 11679162Abstract: Provided in the present invention is an anti-5T4 antibody-drug conjugate and the use thereof. In particular, provided in the present invention is an anti-5T4 antibody-drug conjugate. Also provided in the present invention are the pharmaceutical use of the anti-5T4 antibody-drug conjugate and the effect thereof in inhibiting or preventing tumors.Type: GrantFiled: January 8, 2018Date of Patent: June 20, 2023Assignee: HANGZHOU ADCORIS BIOPHARMA CO., LTD.Inventors: Zhenwei Miao, Tong Zhu, Alisher B. Khasanov, Sheldon Cao, Zhaohui Li, Min Wu
-
Patent number: 11673944Abstract: The invention is directed to methods of treatment of Alzheimer's disease and other tauopathies, via the administration of antibodies having specificity to abnormal forms of tau protein, the antibodies showing no binding and/or reactivity to a normal tau protein and being administered under conditions and in amounts effective to prevent or treat Alzheimer's disease or other tauopathies. In certain embodiments, the antibodies are selective for soluble truncated tau protein truncated at (i) its C-terminus after the glutamic acid residue Glu391, or (ii) at the aspartic acid residue Asp421, or (iii) at its N-terminus at the aspartic acid residue Asp13, or (iv) a combination of (i)-(iii). Further aspects of the invention are directed to the administration of an immunogen comprising an abnormal tau, preferably a soluble truncated tau.Type: GrantFiled: January 14, 2021Date of Patent: June 13, 2023Assignee: TauC3 Biologics LimitedInventor: Daniel G. Chain
-
Patent number: 11667699Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: July 30, 2020Date of Patent: June 6, 2023Assignee: Alector LLCInventors: Jeonghoon Sun, Wei-Hsien Ho, Muhammad A. Alhawagri, Philip Ling Kong, Herve Rhinn, Hua Long, Karpagam Srinivasan, Ananya Mitra, Daniel P. Bermingham, Klaus-Dieter Heger, Santiago Viveros Salazar, Francesca Cignarella, Ilaria Tassi, Tina Schwabe, Angie Grace Yee, Arnon Rosenthal
-
Patent number: 11666659Abstract: Disclosed herein is a monoclonal antibody or a derivative thereof that specifically binds to human plasmalemma vesicle-associated protein (PLVAP, PV-1), including antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody light chain variable region, and antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody heavy chain variable region. The invention also provides a preparation process of a human-mouse chimeric antibody and amino acid sequences of the antibody heavy chain variable region and the antibody light chain variable region. The monoclonal antibody or derivative thereof can be used as a component of a pharmaceutical composition or prepared into a suitable medicament, administered alone or combined with other medications such as anti-VEGF monoclonal antibody and the like, for treating choroidal neovascularization fundus diseases and other angiogenesis/osmosis-related diseases.Type: GrantFiled: September 27, 2018Date of Patent: June 6, 2023Assignee: HUALAN GENETIC ENGINEERING CO., LTD.Inventors: Xiaoqi Song, Zui Chen, Hongqun Hu, Guifang Zhou, Jinling Fan, Qunmin Zhou
-
Patent number: 11661447Abstract: Provided herein are compositions, systems, kits, and methods for expressing a peptide of interest, such as Apolipoprotein H (ApoH), also known as ?2-glycoprotein I (?2GPI), at increased levels using a non-ApoH signal peptide (e.g., a signal peptide that permits increased protein export from cells). Also provided herein are compositions, systems, kits, and methods for employing such recombinant ApoH with a non-ApoH signal peptide to detect subject Apolipoprotein H antibodies in a sample from a subject (e.g., to diagnose antiphospholipid syndrome in a subject).Type: GrantFiled: August 3, 2018Date of Patent: May 30, 2023Assignee: The Cleveland Clinic FoundationInventors: Keith McCrae, Sergei Merkulov, Ravi K. Alluri
-
Patent number: 11643457Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.Type: GrantFiled: October 29, 2019Date of Patent: May 9, 2023Assignee: Prothena Biosciences LimitedInventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
-
Patent number: 11634481Abstract: The present disclosure relates to the field of immunology, in particular to a B-cell epitope of Trichinella spiralis cysteine protease inhibitor, a hybridoma cell line, a monoclonal antibody and uses thereof. The present disclosure provides a hybridoma cell line that can generate anti-WN10 antibody, and identifies the specific B-cell epitope of WN10 protein recognized by the monoclonal antibody. These are of great significance for the diagnosis of trichinellosis, for the establishment of competitive ELISA for detecting antibodies and sandwich ELSIA for detecting circulating antigens, for the detection of Trichinella spiralis in different hosts and for the development of subunit vaccines.Type: GrantFiled: December 19, 2020Date of Patent: April 25, 2023Assignee: JILIN UNIVERSITYInventors: Xiaolei Liu, Mingyuan Liu, Yong Yang, Yan Liu
-
Patent number: 11633496Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.Type: GrantFiled: September 8, 2022Date of Patent: April 25, 2023Assignee: Dyne Therapeutics, Inc.Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
-
Patent number: 11634484Abstract: The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.Type: GrantFiled: April 24, 2019Date of Patent: April 25, 2023Assignee: Neuracle Science Co., Ltd.Inventors: Bongcheol Kim, Dong Sik Kim, Soon-Gu Kwon
-
Patent number: 11629190Abstract: Disclosed are isolated single heavy chain variable (VHH) monoclonal antibodies, antigen binding fragments thereof, and bispecific antibodies include these VHH monoclonal antibodies, wherein the VHH monoclonal antibody or antigen binding fragment specifically binds a canine programmed death (PD)-1. Nucleic acid molecules encoding these VHH monoclonal antibodies and antigen binding fragments are also disclosed, as are expression vectors including these nucleic acid molecules and host cells including these expression vectors. Methods of detecting canine PD-1, and methods of increasing cytotoxic T cell activity and treating tumors are also disclosed.Type: GrantFiled: August 13, 2020Date of Patent: April 18, 2023Assignee: Oregon State UniversityInventors: Dan Vincent Mourich, Carl E. Ruby, Shay Bracha, Christopher Keith Cebra